24 results about "Virus inhibitors" patented technology

Provided in the present application are a cyclic peptide mutant and use and product thereof for the preparation of a coronavirus inhibitor, belonging to the technical field of cyclic peptide drugs. The present application is optimized on the basis of the cyclic peptide 6L3-3P11R. The obtained cyclic peptide mutant can resist the enzyme digestion effect of pancreatic enzymes and exhibits further improved antiviral activity, which is of great significance for expanding antiviral applications of cyclic peptide drugs.

The application provides a whole-process cold-chain preservation method for fresh large yellow croaker, which is targeted to enzyme inhibition and gradient microenvironment regulation. The method provided by the application comprises the following steps: 1, soaking the freshly caught large yellow croaker in seawater containing endogenous protease inhibitor peptides of the large yellow croaker within 30 minutes after catching, and reducing the core temperature of the fish body to 3-4 DEG C; after the soaking is completed, the surface moisture of the fish body is blown dry with sterile wind; 2, packaging the large yellow croaker after the surface moisture of the fish body is blown dry, and storing the packaged large yellow croaker in an environment with a temperature of-0.5-1 DEG C and a relative humidity of 65%-75%, so as to realize the preservation of the fresh large yellow croaker. The method provided by the application can greatly improve the preservation effect, and the endogenous protease inhibitor peptides of the large yellow croaker do not destroy the nutritional components of the fish meat, do not change the original flavor, have no chemical preservative residues, meet the green food standard, and are safer than the existing chemical preservation and soaking preservation technologies.

The present disclosure is generally related to recombinant microbial cells expressing heterologous proteins of interest. Certain aspects of the disclosure are therefore related to, inter alia, recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the instant disclosure are particularly suitable for use in the expression, production and secretion of heterologous proteins.

The application discloses an amino benzene sulfonamide derivative and application thereof. The structural general formula of the amino benzene sulfonamide derivative is shown in the following formula. The amino benzene sulfonamide derivative has good pepsin inhibitory activity, can effectively block the adhesion and reactivation of pepsin in the pharyngeal mucosa, and has super high selectivity in the internal proteinase family compared with other non-specific protease inhibitors, thereby significantly reducing the off-target risk of normal physiological proteases in the human body. In addition, the compound is particularly suitable for local spray administration in the throat, can maintain a high concentration in the lesion site, and overcomes the defect of traditional oral antacid drugs in the insufficient effect on non-acid reflux, thereby providing a new solution for the treatment of throat reflux diseases.

A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and / or human cathepsin L inhibitor, and / or may be used in the preparation of a medicament for treating and / or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and / or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.

This invention relates to an azabicyclo[3.1.0]hexane derivative that can be used as a 3C-like protease inhibitor. This azabicyclo[3.1.0]hexane derivative can be used to treat fever, nausea, vomiting, headache, dyspnea, fatigue, respiratory tract infection, olfactory and gustatory disturbances and their complications, or combinations thereof, caused by novel coronavirus infection.

This invention discloses a method for protein extraction and mass spectrometry pretreatment from methanogenic bacteria, belonging to the field of protein extraction technology. The method involves pretreating a methanogenic bacteria enrichment culture to remove inorganic salt ions and other impurities, resulting in a pretreated culture. Then, a lysis buffer composed of sodium dodecyl sulfate, Tris-HCl buffer, and a protease inhibitor is added to the pretreated culture, followed by ultrasonic disruption to obtain a cell lysate, from which a crude protein extract solution is obtained. Finally, the protein extract is extracted from the crude protein extract solution. This invention significantly improves protein extraction efficiency and peptide purity by optimizing the extraction process and subsequent enzymatic digestion, while preserving the methanogenic activity of the extracted protein as much as possible, providing more accurate and reliable sample support for downstream protein mass spectrometry analysis.

This invention discloses the application of a Trichinella spiralis cysteine ​​protease inhibitor in acute myocardial infarction and subsequent ventricular remodeling, belonging to the field of medicinal chemistry. This invention provides a drug that can prevent, alleviate, and / or treat acute myocardial infarction and subsequent ventricular remodeling. The active ingredient of this drug is the Trichinella spiralis cysteine ​​protease inhibitor cystatin, abbreviated as rTs-Cys. rTs-Cys can effectively delay acute myocardial infarction and inflammatory response in mice, reduce the infarct area, improve cardiac function deterioration, and reverse organ pathological damage, providing a new approach for the clinical treatment of acute myocardial infarction and subsequent ventricular remodeling.

Provided is a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or pharmaceutically acceptable salt thereof, and use thereof for preparing an antiviral protease inhibitor drug.

The present disclosure provides a compound shown in formula (I) or formula (II), which has good protease inhibitory activity and can be used as a peptidomimetic protease inhibitor.

The application discloses application of a medicine for inhibiting HIF-1 alpha in prevention and treatment of fever with thrombocytopenia syndrome, and belongs to the technical field of biotechnology. HIF-1α The application provides the following application: application of a substance for inhibiting gene expression in preparation of an SFTSV virus inhibitor or in preparation of a product for treating or / and preventing SFTSV virus infection; application of a substance for inhibiting HIF-1 alpha protein activity in preparation of an SFTSV virus inhibitor or in preparation of a product for treating or / and preventing SFTSV virus infection; and application of a substance for reducing HIF-1 alpha protein content in preparation of an SFTSV virus inhibitor or in preparation of a product for treating or / and preventing SFTSV virus infection.

The invention relates to a method for generating in a single step a library of recombinant baculoviruses for screening for a protein of interest, starting from a pooled-library of poly-nucleotides each encoding a different protein. Insect cells are infected with a pooled-library of baculoviruses at a very low multiplicity of infection (MOI) leading to the situation where the majority of cells are infected by a single baculovirus. The pool of cells is then treated with a viral inhibitor which prevents secreted baculoviruses from penetrating other cells without affecting, either the capacity of the cell to express the target protein, nor intracellular viral replication and accumulation.

The present disclosure provides a compound represented by formula (I) or formula (II), which has good protease inhibitory activity and can be used as a peptidomimetic protease inhibitor.

This invention provides a receptor-binding domain polypeptide and its application in the preparation of fish lymphocystis virus inhibitors, belonging to the field of polypeptide technology. The amino acid sequence of the polypeptide is SEQ ID NO:1. This polypeptide can be used to prepare products for inhibiting LCDV infection, exerting its effect by blocking the binding of the virus to the VDAC2 receptor. In vitro experiments show that this polypeptide has significant concentration-dependent antiviral activity. Simultaneously, this polypeptide can also be used for VDAC2 labeling and localization analysis. The binding domain is highly conserved in various LCDV subtypes, showing broad application potential. The polypeptide of this invention has a simple structure, is easy to synthesize, and can be used to develop anti-LCDV drugs and related biological products.

Advantageous specific symmetric diaryl hydantoin compounds are provided that have surprising activity as protease inhibitors against the main protease of coronavirus (MPRO), and thus can be used to treat a host in need thereof with a coronavirus including the SARS CoV-2 virus or a seasonal coronavirus in a host.

This invention discloses a phased regulated culture method for the directed accumulation of microbial products, comprising the following steps: Step 1, cell proliferation stage culture; Step 2, metabolic diversion stage culture; Step 3, product-directed synthesis stage culture; Step 4, product stable accumulation stage culture. This invention constructs a four-stage precise regulation system, with each stage having a clear target and corresponding parameter regulation strategy, achieving spatiotemporal separation of cell growth and product synthesis, avoiding metabolic flux competition, and significantly improving the accumulation efficiency of the target product. This invention designs dedicated culture medium formulations and inducer addition strategies for each stage, directionally guiding metabolic flux towards target product synthesis, reducing byproduct generation, and lowering subsequent purification costs. In the product stable accumulation stage, this invention adds protease inhibitors and regulates low-temperature, low-speed conditions, effectively reducing product degradation and improving product yield and stability.

This invention provides solubilizers that have been identified as effectively dissolving nonpolar protease inhibitors in a liquid environment while stabilizing enzymes, preferably hydrolases. Methods for stabilizing and dissolving proteases and protease inhibitors in a liquid composition containing such solubilizers are also provided, as well as methods for cleaning soiled fabrics or tableware using a liquid composition containing such solubilizers.

The invention provides novel compounds that are potent inhibitors of main protease (MPro) and pharmaceutical compositions and methods thereof for treating MPro-associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).

This invention discloses a cancer vaccine targeting tumor-associated macrophages, its preparation method, and its applications, belonging to the field of biomedical technology. The cancer vaccine comprises hybrid membrane vesicles, a targeting module, and a protease inhibitor. The targeting module is connected to the surface of the hybrid membrane vesicles, and the protease inhibitor is loaded into the lumen of the hybrid membrane vesicles. The hybrid membrane vesicles are obtained by fusing bacterial outer membrane vesicles and tumor cell membrane vesicles, and the targeting module is bonded to the tumor cell membrane vesicles. This cancer vaccine, by efficiently targeting tumor-associated macrophages and dually regulating their phenotype and function, holds the potential to transform them from a pro-tumor population into an anti-tumor population, providing broader application prospects for cancer treatment.

The present disclosure provides compounds with increased metabolic stability for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of the present disclosure also include methods of treating the virus infection in a subject with compounds with increased metabolic stability.

This invention relates to the field of biotechnology, specifically to a composite quality control product for gastric tumor markers and its preparation method. The composite quality control product comprises gastric tumor marker antigens and a quality control buffer solution. The quality control buffer solution comprises 1-10% protein protectant, 0.01-3% surfactant, 2-20% thickening antioxidant, 0.5-500 mg / L protease inhibitor, 0.01-3% metal ion chelating agent, and 0.5-10% buffer matrix. The gastric tumor marker antigens include G17, PGII, and CA72-4. This invention, by addressing the interactions between G17, PGII, and CA72-4 antigens, achieves composite quality control for eight gastric tumor markers. This covers the quality control of four conventional gastric tumor detection reagents (PGI, PGII, G17, and CA72-4) and four broad-spectrum tumor detection reagents (AFP, CEA, CA19-9, and CA242), which is of significant importance for clinical gastric tumor screening.

The present disclosure relates to a compound of formula (I) or a salt, solvate, stereoisomer or prodrug thereof as a 3CL protease inhibitor. The compound can be used for treating coronavirus-related diseases or disorders. (I).

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.

This invention particularly provides compounds, pharmaceutical compositions, and methods related to the treatment of viral infections caused by coronaviruses or enteroviruses. The invention provides compounds of formulas (I), (II), and (III) and methods for using said compounds in a therapeutic manner. These compounds are peptide mimics of the coronavirus protease 3CL and are suitable for treating conditions caused by viral infections, including COVID-19.